Colossal Biosciences aims to leverage genomics technology and advanced sciences to bring back animals like the woolly mammoth and the dodo bird from extinction. But is there a viable business model?
CRISPR is an exciting technology that enables a new class of diagnostic tests and therapies for congenital diseases. Mammoth Biosciences is a leading private company in the space.
Neuralink is Elon Musk’s attempt to bridge the gap between the digital world and the human brain. The medical applications of a brain-machine interface could improve the lives of millions. Though Musk’s ultimate goal is to merge AI and I.
eGenesis has developed a gene editing process to make pig organs transplantable into humans. CRISPR has the potential to reduce immune reject, thus creating a long-term solution to the global organ donor shortage.
Thanks to its wealthy founder, Neuralink gets most of the brain-computer interface (BCI) news coverage. But an Australian/U.S.-based company is further along the FDA approval process, and its device is less intrusive than its competitors.
Freenome is on a mission to detect cancer early to aid in doctors’ ability to treat it and save lives. Retail investors own this innovative startup today, potentially years before an acquisition or public offering.